AIM ImmunoTech (AIM) announced that data were published on Roswell Park Comprehensive Cancer Center’s Phase 1 study evaluating AIM ImmunoTech’s drug Ampligen as a component of a chemokine ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback